Osteoarthritis Pain - Pipeline Review, H2 2011

Published by: Global Markets Direct

Published: Sep. 28, 2011 - 84 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Osteoarthritis Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Osteoarthritis Pain
Osteoarthritis Pain Therapeutics under Development by Companies
Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Osteoarthritis Pain Therapeutics - Products under Development by Companies
Osteoarthritis Pain Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Osteoarthritis Pain Therapeutics Development
Genzyme Corporation
Johnson & Johnson
Abbott Laboratories
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
BioDelivery Sciences International, Inc.
Cephalon, Inc.
Glenmark Pharmaceuticals Ltd.
Pfizer Inc.
Menarini Group
Addex Pharmaceuticals
Cerimon Pharmaceuticals, Inc.
Array BioPharma Inc.
Neurotune AG
Grunenthal GmbH
Rottapharm SpA
QRxPharma Limited
Winston Pharmaceuticals, Inc.
SantoSolve AS
Apimeds, Inc.
Osteoarthritis Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CEP-33237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH-797804 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-11624 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nucynta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-797 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEMA Buprenorphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MoxDuo CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civamide Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRB 0022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-39439335 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gen-S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Apitoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civanex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intra-Articular Civamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC 15300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-652 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
2PX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEN16132 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-578 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR114137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carbamazepine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2828360 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GABA-BR PAM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THA902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteoarthritis Pain Therapeutics - Drug Profile Updates
Osteoarthritis Pain Therapeutics - Discontinued Products
Osteoarthritis Pain - Featured News
Aug 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week 2010
Aug 30, 2010: J&JPRD And Grunenthal Report Phase III Study Data Comparing Tapentadol ER To Placebo In Patients With Chronic Osteoarthritis Knee Pain
Aug 19, 2010: Lilly Reports Approval Recommendation From FDA Advisory Committee For Expanding Pain Indications For Cymbalta
Jun 19, 2010: SantoSolve AS Present 2PX at EULAR congress
Nov 17, 2009: SantoSolve Completes Patient Enrollment In First Pivotal Phase III Trial In Osteoarthritis
Mar 12, 2009: Glenmark's GRC 15300 To Enter Phase I Trials
Jan 24, 2009: Glenmark Pharma To Develop GRC 15300
Nov 19, 2008: Pharmos Announces Clinical Results From Phase IIa Trial Of Topical Diclofenac NanoEmulsion Cream
Dec 03, 2007: SantoSolve Reports Positive Phase II Results In Patients With Osteoarthritis
Mar 31, 2005: First Head-To-Head Study to Compare Lidoderm Patch and Celebrex in Treating Pain Associated With Osteoarthritis of the Knee
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Osteoarthritis Pain, H2 2011
Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Genzyme Corporation, H2 2011
Johnson & Johnson, H2 2011
Abbott Laboratories, H2 2011
Sanofi-Aventis, H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
BioDelivery Sciences International, Inc., H2 2011
Cephalon, Inc., H2 2011
Glenmark Pharmaceuticals Ltd., H2 2011
Pfizer Inc., H2 2011
Menarini Group, H2 2011
Addex Pharmaceuticals, H2 2011
Cerimon Pharmaceuticals, Inc., H2 2011
Array BioPharma Inc., H2 2011
Neurotune AG, H2 2011
Grunenthal GmbH, H2 2011
Rottapharm SpA, H2 2011
QRxPharma Limited, H2 2011
Winston Pharmaceuticals, Inc., H2 2011
SantoSolve AS, H2 2011
Apimeds, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Osteoarthritis Pain Therapeutics - Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Osteoarthritis Pain, H2 2011
Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Abstract

Osteoarthritis Pain - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Osteoarthritis Pain - Pipeline Review, H2 2011', provides an overview of the Osteoarthritis Pain therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. 'Osteoarthritis Pain - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Osteoarthritis Pain.
  • A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Osteoarthritis Pain therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.